Income StatementBalance SheetCash FlowSegments
Gilead Sciences logo

Gilead Sciences Cash Flow Statement

Operating, investing, and financing cash movements

Gilead Sciences generated $10.8B in operating cash flow over the trailing twelve months. After $576.0M in capital expenditures, free cash flow was $10.2B. Free cash flow increased 0.0% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$10.8BNet Cash From Investing (TTM)-$2.6BNet Cash From Financing (TTM)-$8.6BCapital Expenditures (TTM)$576.0MDepreciation And Amortization Cf (TTM)$2.4BNet Change In Cash (TTM)-$531.0M
Latest FilingQ1 2026
Report Date2026-05-07
Market Cap$160.99B
P/E Ratio17.47
ROE43.27%

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquisitions, net of cash acquired$75.0M$273.0M$21.0M$167.0M$609.0M$109.0M
Capital expenditures$147.0M$104.0M$107.0M$147.0M$205.0M$117.0M
Payment for (Proceeds from) Other Investing Activity—$23.0M———$17.0M
Payments to Acquire Other Investments—$16.0M———$19.0M
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale—$0.0———$36.0M
Sale of investments—$0.0———$2.5B
Net cash from investing activities-$225.0M-$415.0M-$2.1B-$427.0M-$1.8B$1.8B
Purchases of investments$39.0M$16.0M$2.0B-$1.9B$14.0M$525.0M

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Change in fair value of equity securities—-$426.0M———$142.0M
Change in accounts payable—-$105.0M-$162.0M$230.0M-$95.0M-$67.0M
Change in accounts receivable-$72.0M-$79.0M$292.0M$333.0M—-$134.0M
Change in accrued liabilities$305.0M-$244.0M-$166.0M$811.0M—-$702.0M
Change in income taxes payable/receivable—-$552.0M-$1.3B-$122.0M-$134.0M-$29.0M
Change in inventories$226.0M$223.0M$175.0M$515.0M$123.0M$52.0M
Deferred income taxes-$379.0M-$199.0M-$178.0M$659.0M—$179.0M
Net cash from operating activities$3.0B$1.8B$827.0M$4.1B$3.3B$2.5B
Net income$1.8B$1.3B$2.0B$3.1B$2.2B$2.0B
Amortization—$599.0M———$596.0M
Depreciation—$97.0M———$93.0M
Increase (Decrease) in Prepaid Expense and Other Assets—-$12.0M———-$5.0M
Other Noncash Income (Expense)—-$91.0M———-$183.0M
Acquired in-process research and development—$253.0M———$107.0M
Stock-based compensation$222.0M$209.0M$225.0M$230.0M$230.0M$218.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Dividends paid$973.0M$1.0B$994.0M$1.0B$994.0M$1.0B
Other, net—-$176.0M———-$179.0M
Repayments of Debt—$1.8B———$2.8B
Net cash from financing activities—-$3.4B-$1.6B-$1.5B-$1.3B-$4.2B
Proceeds from issuance of common stock$173.0M$252.0M$27.0M$97.0M$32.0M$166.0M
Repurchases of common stock$350.0M$730.0M$527.0M$435.0M$230.0M$419.0M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$2.8B$1.7B$720.0M$4.0B$3.1B$2.4B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$55.0M$19.0M$73.0M-$5.0M$5.0M-$11.0M
Net increase (decrease) in cash$5.0B-$2.1B-$2.8B$2.2B$0.0$65.0M